Clinical Trial Update: SL-11047 in Treating Patients With Relapsed or Refractory Lymphoma [Phase 1]

View source ↗

Summary

This update reports the completion of a Phase 1 clinical trial evaluating SL-11047 in patients with relapsed or refractory lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• SL-11047

Snippet

Sponsor: Progen Pharmaceuticals | Conditions: Lymphoma | Phase 1 | Status: COMPLETED